Drug ResearchPub Date : 2025-02-01Epub Date: 2025-01-13DOI: 10.1055/a-2499-3067
Ainaz Mihanfar, Faezeh Asghari, Maryam Majidinia
{"title":"WEE1 Inhibition by AZD1775 Augments Colorectal Cancer Cells Susceptibility to VE-822-induced DNA Damage and Apoptosis.","authors":"Ainaz Mihanfar, Faezeh Asghari, Maryam Majidinia","doi":"10.1055/a-2499-3067","DOIUrl":"10.1055/a-2499-3067","url":null,"abstract":"<p><p>WEE1 is a key tyrosine kinase involved in the cell cycle regulation with potent anticancer effects in various cancer types including colorectal cancer. Recent studies have focused on the potential of combinational inhibition of Ataxia Telangiectasia and Rad-3-related protein (ATR) and WEE1 in increasing apoptosis in cancer cells. Therefore, this study investigates the effects of inhibiting WEE1, by employing AZD1775, on colorectal cancer cells' susceptibility to VE-822-induced DNA damage and apoptosis.SW-480 and HT-29 cells were treated with AZD1775 and VE-822, alone and in combination. MTT assay was used to assess cell proliferation and viability. The mRNA levels of ATR, checkpoint kinase 1 (CHK1), WEE1, ribonucleotide reductase (RR) catalytic subunit M1 (RRM1) and RRM2 were measured by qRT-PCR. Cellular γ-(H2A histone family member X) H2AX levels were measured by Western blot. Analyses were conducted using ELISA to assess 8-Oxo-2'-deoxyguanosine (8-oxo-dG) levels. Lactate dehydrogenase (LDH) and ELISA death assays were used to assess apoptosis.The SW-480 and HT-29 cells have low proliferation rate when treated with VE-822 and AZD1775. The IC50 value for VE-822 was 1.3 μM and 1.6 μM in SW480 and HT-29, respectively. Also, this value for AZD1775 in SW480 was 140 nM and in HT-29 was 185 nM. The expression levels of ATR, CHK1, WEE1, RRM1, and RRM2 were significantly downregulated in both cell lines treated with combination of VE-822 and AZD1775 (P<0.05). DNA damage markers, including γ-H2AX and 8-oxo-dG were upregulated in these cells. Simultaneous treatment with VE-822 and AZD177 increased apoptosis capacity of both cell lines.The inhibition of WEE1 via AZD1775 potentiated the anticancer effects of ATR inhibitor, VE-822, in combating colorectal cancer via targeting DNA damage.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"66-75"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2025-02-01Epub Date: 2025-01-15DOI: 10.1055/a-2507-5528
Khalid M Alkharfy, Ajaz Ahmad, Mohammad Raish, Maha F Alenazy
{"title":"Thymoquinone Mediates Müller Cell Apoptosis via miR-29b/SP1 Pathway: A Potential Therapeutic Approach in Diabetic Retinopathy.","authors":"Khalid M Alkharfy, Ajaz Ahmad, Mohammad Raish, Maha F Alenazy","doi":"10.1055/a-2507-5528","DOIUrl":"10.1055/a-2507-5528","url":null,"abstract":"<p><p>This study aims to explore the therapeutic potential of thymoquinone (TQ) in DR by assessing its effects on Müller cell apoptosis through modulation of the miR-29b/SP1 pathway in a diabetic animal model.Healthy C57BL/6 mice (25 g) were used in the study. Retinal samples were collected from both normal and diabetic mice subjected to various treatments: TQ (1 mg/kg/day), glibenclamide (GLB, 250 mg/kg/day), sitagliptin (STG, 10 mg/kg/day), and metformin (MET, 5 mg/kg/day) over a period of 28 days. The study measured miR-29b and SP1 mRNA levels using qRT-PCR. Protein expressions of SP1, Bax, and bcl-2 were analyzed through western blotting, while Caspase-3 activity using an ELISA assay kit, and apoptosis levels by annexin V.TQ administration resulted in a 52% reduction in blood glucose levels. Similarly, GLB, STG, and MET treatments reduced blood glucose by 60%, 57%, and 61%, respectively (<i>p<0.05</i>). In addition, TQ upregulated miR-29b by 51.28% and downregulated SP1 mRNA by 32.52% (<i>p<0.05</i>). Bax protein expression levels were decreased by 64.99%, while Bcl-2 protein expression increased by 62.92% in the TQ treatment group as compared to the untreated diabetic controls. Furthermore, Caspase-3 activity was downregulated by 40.03% with TQ treatment (<i>p<0.05</i>). Interestingly, the effect TQ on SP1 mRNA expression was inhibited by a miR-29b blocker (<i>p<0.05</i>), while an miR-29b mimic enhanced this effect; this was associated with a mitigation of apoptosis of retinal Müller cells as measured by flow cytometry (<i>p<0.05</i>).These results indicate that TQ might be a possible option for DR <i>via</i> its effect on the miR-29b/SP1 pathway; and therefore, playing a significant role in the mechanism against cell death.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"76-83"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Repeated injections of isovaline lead to analgesic tolerance and cross-tolerance to salicylate but not to morphine in male mice.","authors":"Maryam Moghimian, Reza Nazari-Motlagh, Seyed Sajjad Alavi-Kakhki, Mahdi Khorsand Ghaffari, Elham Akbari, Masoumeh Fani, Mehdi Sadegh, Masoumeh Gholami","doi":"10.1055/a-2481-6129","DOIUrl":"10.1055/a-2481-6129","url":null,"abstract":"<p><p>Tolerance to the antinociceptive effects of opioids is a major concern. Studies have shown that chronic use of non-steroidal anti-inflammatory (NSAIDs) causes significant tolerance and cross-tolerance to morphine. Chronic NSAIDs use can increase the risk of certain diseases, such as peptic ulcers, and exacerbate others, like heart failure. Therefore, developing novel pharmacological approaches could provide considerable benefits for chronic therapeutic procedures. Isovaline with a chemical structure similar to glycine and GABA induce a significant analgesic effect through GABA-B receptors. In this study, we investigated the impact of both short-term and long-term use of isovaline on the immediate response to pain, as well as the development of analgesic tolerance through daily injection (i.p.) of isovaline (100 mg/kg) for 5 days in male Balb/c mice. Additionally, on day 6, we examined the potential for cross-tolerance between isovaline and sodium salicylate (300 mg/kg) or morphine (5 mg/kg). The findings showed that isovaline injection resulted in a delayed onset of analgesic effect, a lowered peak effect, and less cumulative pain relief compared with sodium salicylate and morphine. This analgesic effect gradually decreased over the five days of isovaline injection. When sodium salicylate was injected into isovaline-tolerant mice, the antinociceptive effect decreased, suggesting cross-tolerance to sodium salicylate. However, no such tolerance was observed following morphine injection. Accordingly, it seems that chronic isovaline may interact with the sodium salicylate analgesic pathway but not with morphine.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"60-65"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synthesis and Characterization of Acacia-Stabilized Doxorubicin-Loaded Gold Nanoparticles for Breast Cancer Therapy.","authors":"Laxmi Devi, Poonam Kushwaha, Tarique Mahmood Ansari, Amit Rao, Ashish Kumar","doi":"10.1055/a-2418-2200","DOIUrl":"10.1055/a-2418-2200","url":null,"abstract":"<p><p>The targeted delivery of drugs is vital in breast cancer treatment due to its ability to produce long-lasting therapeutic effects with minimal side effects. This study reports the successful development of doxorubicin hydrochloride (DOX)-loaded colloidal gold nanoparticles stabilized with acacia gum (AG). Optimization studies varied AG concentrations (0.25% to 3% w/v) to determine optimal conditions for nanoparticle synthesis. The resulting acacia stabilized gold nanoparticles (AGNPs) were characterized using various techniques including high-resolution transmission electron microscopy (HR-TEM), powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), ultraviolet-visible spectroscopy, Fourier-transform infrared spectroscopy (FT-IR), field emission scanning electron microscopy (FE-SEM), and selected area electron diffraction (SAED). In vitro drug release studies demonstrated a higher release rate of DOX in sodium acetate buffer (pH 5.0) compared to phosphate buffer saline (pH 7.4), suggesting an enhanced therapeutic efficacy in acidic tumor environments. Cytotoxicity of DOX-AGNPs and free DOX was assessed in human breast cancer cells (MDA-MB-231). The DOX-AGNPs exhibited significantly greater cytotoxicity, indicating enhanced efficacy in targeting cancer cells. This enhancement suggests that adsorbing DOX on the surface of gold nanoparticles can improve drug delivery and effectiveness, potentially reducing side effects compared to pure DOX and traditional delivery methods. Stability tests conducted over six months at 25±1°C showed significant changes in particle size and PDI, suggesting limited stability under these conditions. Overall, the acacia-stabilized gold nanoparticles synthesized in this study exhibit promising characteristics for drug delivery applications, particularly in cancer therapy, with effective drug loading, controlled release, and favorable physicochemical properties.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"34-44"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2025-01-01Epub Date: 2024-10-15DOI: 10.1055/a-2419-9616
Bahareh Farasati Far, Partow Mirzaee Saffari, Razieh Mohammad Jafari, Ramin Goudarzi, Ahmad Reza Dehpour, Alireza Partoazar
{"title":"Phosphatidylserine Topically Attenuates Imiquimod-induced Psoriasis Through Inflammation Inhibition in Mice.","authors":"Bahareh Farasati Far, Partow Mirzaee Saffari, Razieh Mohammad Jafari, Ramin Goudarzi, Ahmad Reza Dehpour, Alireza Partoazar","doi":"10.1055/a-2419-9616","DOIUrl":"10.1055/a-2419-9616","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic skin condition that is associated with persistent inflammation and skin lesions. Topical therapy has been a promising approach to the alleviation of psoriasis through the application of anti-inflammatory agents. Phosphatidylserine (PS) administration has shown anti-inflammatory effects in the trials. Consequently, the objective of this study was to evaluate the effects of topical PS on the potential improvement of an imiquimod (IMQ)-induced psoriasis model. Additionally, cyclosporine A was utilized as a comparative anti-psoriatic agent in our study.</p><p><strong>Methods: </strong>The psoriasis model was established by topically applying IMQ to the dorsal skin of mice once daily for five consecutive days. The efficacy of topical PS was assessed using the Psoriasis Area and Severity Index (PASI) score to evaluate skin lesions. Subsequently, the skin samples were analyzed using Baker's scoring system, Masson's trichrome staining, immunohistochemistry, and real-time PCR analysis.</p><p><strong>Results: </strong>IMQ-induced plaque-type psoriasis resulted in a significant increase <i>(P<0.05)</i> in dermal thickness, hyperkeratosis, PASI score, and inflammatory cytokines at the lesion site. The topical PS and cyclosporine A significantly <i>(P<0.05)</i> reduced PASI score and dermal thickness, while also alleviating erythema and scaling when compared to untreated mice. Furthermore, biomolecular assessments revealed that PS significantly <i>(P<0.05)</i> inhibited the gene expression of IL-17, IL-23, and TNF-α cytokines in the IMQ-induced lesions.</p><p><strong>Conclusion: </strong>Topical PS may pointedly alleviate psoriasis through the inhibition of inflammation. The beneficial effects of the PS recommend further investigation in both experimental and clinical studies in the control of skin psoriasis.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"12-20"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2025-01-01Epub Date: 2024-10-15DOI: 10.1055/a-2423-3533
J S Gayathri, S Swathi Krishna, M P Rakesh
{"title":"Tyrosine Kinase Inhibitor Induced Proteinuria - A Review.","authors":"J S Gayathri, S Swathi Krishna, M P Rakesh","doi":"10.1055/a-2423-3533","DOIUrl":"10.1055/a-2423-3533","url":null,"abstract":"<p><p>Tyrosine Kinase inhibitor (TKI) is a class of drugs that interfere with protein kinases' signal transduction pathways through an array of inhibitory mechanisms. Tyrosine kinases (TK) have an inevitable role in downstream signal transduction and the proliferation of tumour cells. Hence, tyrosine kinase inhibitors (TKIs) are frequently employed as anti-neoplastic agents in the treatment of colon, breast, kidney, and lung cancers. They can be used as single or combination therapy with other targeted therapies. It is understood that TKIs pose a risk of developing proteinuria in some patients as it can primarily result in dysfunction of the split diaphragm, constriction or blockage of capillary lumens mediated by the basement membrane, acute interstitial nephritis, or acute tubular necrosis. This paper reviews the mechanism of action of TKIs, the pathophysiological mechanism of TKI-induced proteinuria, and its management Fig. 1.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"5-11"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Silico Identification of Promising PDE5 Inhibitors Against Hepatocellular Carcinoma Among Natural Derivatives: A Study Involving Docking and ADMET Analysis.","authors":"Anil Kumar, Dharmendra Rajput, Naveen Gupta, Harpreet Singh, Shivani Chopra, Hitesh Chopra","doi":"10.1055/a-2435-4709","DOIUrl":"10.1055/a-2435-4709","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) represents a significant worldwide health challenge due to its high mortality rate, underscoring the need for advanced therapeutic strategies. This study employs a computer-based method to identify potential phosphodiesterase 5 (PDE5) inhibitors from a library of approved IBS_Scaff 532 natural compounds. PDE5 inhibitors have gained attention for their potential anti-tumor effects. Using molecular docking simulations, the researchers assessed how well these compounds bind to the PDE5 enzyme, which regulates cellular cGMP pathways. Additionally, ADMET profiling predicted the pharmacological and safety properties of candidate inhibitors. Notably, compounds like IBS_NC-0322 and IBS_NC-0320 exhibited favorable ADMET properties and strong binding affinities. These findings suggest their potential as therapeutic agents for treating HCC. While in silico methods serve as valuable screening tools, subsequent experimental validation and clinical trials are essential for confirmation.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"21-33"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2024-11-01Epub Date: 2024-09-26DOI: 10.1055/a-2413-3740
Babita Shukla, Poonam Kushwaha
{"title":"Exploring the HPLC Profiling and Antioxidant Potency in Methanolic Extracts of Curcuma longa L. Rhizomes.","authors":"Babita Shukla, Poonam Kushwaha","doi":"10.1055/a-2413-3740","DOIUrl":"10.1055/a-2413-3740","url":null,"abstract":"<p><p>In this exploration of <i>Curcuma longa</i> Linn., commonly known as turmeric, renowned for its therapeutic history, our study focuses on the bioactive compound curcumin. We established and validated an HPLC method for precise curcumin quantification, complemented by an examination of total phenolic and flavonoid content, as well as antioxidant capabilities in a methanolic extract from <i>C. longa</i> rhizomes obtained through a methanol-based Soxhlet extraction. The HPLC analysis utilized a C18 column with a mobile phase of 70:30 V/V Acetonitrile (ACN) to Water (with 1% Glacial Acetic Acid) under an isocratic elution at 1 mL/min, detection at 420 nm, and a reference standard. The method exhibited notable accuracy, precision, and reproducibility. Antioxidant potential, assessed through DPPH, nitric oxide, and hydroxyl radical scavenging assays, unveiled significant total phenol and total flavonoid quantities, highlighting <i>C. longa's</i> potent antioxidant capacity. The study demonstrated a correlation between antioxidant activities and phenolic and flavonoid concentrations, reinforcing the robustness of our method. In conclusion, this method offers an effective means of quantifying curcumin within <i>C. longa</i> rhizomes and holds promise as a valuable tool for maintaining quality control in the production of this botanical material.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"475-482"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2024-11-01Epub Date: 2024-09-23DOI: 10.1055/a-2401-4700
Meng Zhu, Linghui Tao, Feiye Zhu, Yongsheng Zhang
{"title":"A Comparative Analysis of ADRs under Obeticholic Acid and Ursodeoxycholic Acid in Cholestatic Liver Diseases Using the FAERS Database.","authors":"Meng Zhu, Linghui Tao, Feiye Zhu, Yongsheng Zhang","doi":"10.1055/a-2401-4700","DOIUrl":"10.1055/a-2401-4700","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to compare the safety profiles of OCA and UDCA for the treatment of PBC using the FDA Adverse Event Reporting System database.</p><p><strong>Methods: </strong>We extracted reports for OCA from 2016 to 2023 and UDCA from 2004 to 2023. Demographic details, adverse events (AEs), and concomitant medications were analyzed using descriptive statistics and signal detection methods.</p><p><strong>Results: </strong>The most common for OCA were pruritus (1345 cases, ROR 20.96) and fatigue (528 cases, ROR 3.46). UDCA was more frequently associated with hepatocellular carcinoma (22 cases, ROR 16.37) and type I hypersensitivity reactions (11 cases, ROR 12.77). OCA was also linked to a higher frequency of constipation (161 cases, ROR 3.92) and increased blood alkaline phosphatase levels (145 cases, ROR 44.27).</p><p><strong>Conclusion: </strong>This study reveals distinct safety profiles for OCA and UDCA in the treatment of PBC. OCA is associated with a higher frequency of pruritus, fatigue, constipation, and increased blood alkaline phosphatase levels, while UDCA is linked to hepatocellular carcinoma and type I hypersensitivity reactions. These findings support personalized treatment approaches based on individual patient characteristics.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"464-474"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug ResearchPub Date : 2024-11-01Epub Date: 2024-09-19DOI: 10.1055/a-2406-5340
Samane Jahanabadi, Mohammadreza Riahi Madvar
{"title":"Unraveling the Interplay of 5-hydroxytryptamine-3 and N-methyl-d-aspartate Receptors in Seizure Susceptibility.","authors":"Samane Jahanabadi, Mohammadreza Riahi Madvar","doi":"10.1055/a-2406-5340","DOIUrl":"10.1055/a-2406-5340","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy, a prevalent neurological disorder characterized by recurrent seizures, presents significant challenges in treatment and management. This study aimed to evaluate the effect of tropisetron, a selective 5-HT3 receptor antagonist on pentylenetetrazole (PTZ) - induced seizure in mice by exploring the potential role of the NMDA receptor and inflammatory responses.</p><p><strong>Methods: </strong>For this purpose, seizures were induced by intravenous PTZ infusion. Tropisetron at 1-, 2-, 3-, 5-, 10- mg/kg were administered intraperitoneally 30 minutes before PTZ. To evaluate probable role of NMDA signaling, selective NMDAR antagonists, ketamine and MK-801, were injected 15 minutes before tropisetron. Also, TNF-α level of hippocampus were measured following administration of mentioned drugs in mice.</p><p><strong>Results: </strong>Our results demonstrate that tropisetron displayed a dose-dependent impact on seizure threshold, with certain doses (5 and 10 mg/kg) exhibiting anticonvulsant properties. In addition, the noncompetitive NMDAR antagonists, ketamine (1 mg/kg) and MK-801 (0.5 mg/kg), at doses that had no effect on seizure threshold, augmented the anticonvulsant effect of tropisetron (3 mg/kg). Also, tropisetron led to a reduction in hippocampal TNF-α levels, indicating its anti-inflammatory potential independent of 5-HT receptor activity.</p><p><strong>Conclusion: </strong>In conclusion, we demonstrated that the anticonvulsant effect of tropisetron is mediated by the inhibition of NMDA receptors and a decline in hippocampal TNF-α level. These findings highlight a potential connection between 5-HT3 and NMDA receptors in the pharmacological treatment of inflammatory diseases, such as seizure, warranting further investigation into their combined therapeutic effects.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"456-463"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}